# Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome

> **NCT02875587** · PHASE2 · COMPLETED · sponsor: **Aljazeera Hospital** · enrollment: 170 (actual)

## Conditions studied

- OHSS

## Interventions

- **DRUG:** Cabergoline
- **DRUG:** Calcium gluconate

## Key facts

- **NCT ID:** NCT02875587
- **Lead sponsor:** Aljazeera Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-08
- **Final completion:** 2018-12
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2018-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02875587

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02875587, "Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02875587. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*